Proactive Investors - Run By Investors For Investors

Acasti Pharma granted allowance for patents in 3 more countries for drug candidate Capre

Acasti Pharma (NASDAQ: ACST-CVE:ACST) Co-Founder and Chief Operating Officer Pierre Lemieux joined Steve Darling from Proactive Investors Vancouver to bring news Acasti received 3 new patents for their flagship drug candidate CaPre.

Lemieux talks about what this means for the company going forward and where in the pipeline CaPre is and what trials will happen this year.

View full ACST profile View Profile

Acasti Pharma Inc. Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use